Djokovic holds 80% of Danish biotech building COVID procedure – CEO

Serbian tennis participant Novak Djokovic arrives at Nikola Tesla Airport, right after the Australian Federal Court docket upheld a government final decision to cancel his visa to enjoy in the Australian Open, in Belgrade, Serbia January 17, 2022. REUTERS/Christopher Pike

Register now for Cost-free unlimited obtain to Reuters.com

COPENHAGEN, Jan 19 (Reuters) – Tennis champion Novak Djokovic has an 80% stake of Danish biotech business QuantBioRes, which is aiming to acquire a clinical treatment method to counter COVID-19, the firm’s main government informed Reuters on Wednesday.

CEO Ivan Loncarevic, who explained himself as an entrepreneur, stated the investment decision was produced in June 2020 but declined to say how significantly it was.

QuantBioRes has around 11 scientists performing in Denmark, Australia and Slovenia, in accordance to Loncarevic, who pressured they had been performing on a procedure, not a vaccine.

Register now for Totally free unlimited obtain to Reuters.com

The organization is creating a peptide, which inhibits the coronavirus from infecting the human cell, expects to launch clinical trials in Britain this summertime, he included.

A spokesperson for Djokovic did not promptly reply to a ask for for comment.

The tennis variety a person has stoked world debate about the rights of people who decide not to get vaccinated right after he was deported from Australia on Sunday night time, ruling him out of the Australian Open up. go through much more

Sign-up now for Free of charge unlimited accessibility to Reuters.com

Reporting by Nikolaj Skydsgaard
Enhancing by Alison Williams and Pravin Char

Our Expectations: The Thomson Reuters Have faith in Ideas.